I'ROM GROUP

INFORMATION

2018.9.13: Boehringer Ingelheim, UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica announce conclusion of a collaborative research and development deal to develop a gene therapy for cystic fibrosis based on the vector technology developed by ID Pharma, I’rom Group subsidiary.
2018.8.22: ID Pharma concluded an iPS Cell Generation Technology Licensing Agreement with UK-based Elpis Biomed.
2018.8.21: I’rom Group concludes a strategic partnership agreement with Beroni Group.
2018.6.22: ID Pharma granted EU patent for the technology regarding production of functional classical brown adipocytes from human pluripotent stem cells.
2018.5.28: I’rom Group concludes a strategic partnership agreement with Japanese Bio company Dendrix.
2018.5.11: Summary of Business Results for the Fiscal Year Ended March 31, 2018 [Japan GAAP] (Consolidated)
2018.2.8: Summary of Business Results for the Third Quarter Ended December 31, 2017 [Japan GAAP] (Consolidated)
2018.2.2: ID Pharma concluded an iPS Cell Generation Technology Licensing Agreement with US-based QurAlis Corporation.
2018.1.29: Establishment of a Subsidiary in Hong Kong
2018.1.9: ID Pharma concluded an iPS Cell Generation Technology Licensing Agreement with US-based Q-State Biosciences, Inc..

2018.1.29: Establishment of a Subsidiary in Hong Kong
2017.11.9: I’rom Group announces interim dividends from surplus, with a record date of September 30, 2017.
2017.10.17: I’rom Group concludes a partnership agreement with OKEIOS, a subsidiary of OKWAVE.
2017.8.23: IDT Australia announces the completion of the CMAX transaction.
2017.8.23: I’rom Group completes acquisition of all the shares in CMAX.
2017.3.31: I’rom Group concludes a share exchange agreement with Ethic Co., Ltd.
2017.1.16: UPDATE: From Management
2016.12.15: Our English website is renewed.
2016.10.13: I’rom Group issues its 9th stock acquisition rights (with an amended exercise price) through third party allotment and concludes an agreement (Commit Issue) for a third-party allotment of stock acquisition rights
2016.6.13: I’rom Group outside director Mr. Yoshiyuki Nagai receives The Order of the Sacred Treasure, Gold Rays with Neck Ribbon in spring 2016

2018.9.13: Boehringer Ingelheim, UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica announce conclusion of a collaborative research and development deal to develop a gene therapy for cystic fibrosis based on the vector technology developed by ID Pharma, I’rom Group subsidiary.
2018.8.22: ID Pharma concluded an iPS Cell Generation Technology Licensing Agreement with UK-based Elpis Biomed.
2018.8.21: I’rom Group concludes a strategic partnership agreement with Beroni Group.
2018.6.22: ID Pharma granted EU patent for the technology regarding production of functional classical brown adipocytes from human pluripotent stem cells.
2018.5.28: I’rom Group concludes a strategic partnership agreement with Japanese Bio company Dendrix.
2018.2.2: ID Pharma concluded an iPS Cell Generation Technology Licensing Agreement with US-based QurAlis Corporation.
2018.1.9: ID Pharma concluded an iPS Cell Generation Technology Licensing Agreement with US-based Q-State Biosciences, Inc..
2017.11.27: ID Pharma, Acting in the Role of In-Country Clinical Caretaker, Submits CTN for US Company DiscGenics’ IDCT-001 Clinical Trial
2017.11.13: ID Pharma granted Chinese patent for the technology regarding production of functional classical brown adipocytes from human pluripotent stem cells.
2017.7.11: ID Pharma concluded an iPS Cell Generation Technology Licensing Agreement with UK-based Axol Bioscience.

2018.5.11: Summary of Business Results for the Fiscal Year Ended March 31, 2018 [Japan GAAP] (Consolidated)
2018.2.8: Summary of Business Results for the Third Quarter Ended December 31, 2017 [Japan GAAP] (Consolidated)
2017.11.9: Summary of Business Results for the Second Quarter Ended September 30, 2017 [Japan GAAP] (Consolidated)
2017.8.9: Summary of Business Results for the First Quarter Ended June 30, 2017 [Japan GAAP] (Consolidated)
2017.5.12: Summary of Business Results for the Fiscal Year Ended March 31, 2017 [Japan GAAP] (Consolidated)
2017.2.13: Summary of Business Results for the Third Quarter Ended December 31, 2016 [Japan GAAP] (Consolidated)
2016.11.11: Summary of Business Results for the Second Quarter Ended September 30, 2016 [Japan GAAP] (Consolidated)
2016.8.10: Summary of Business Results for the First Quarter Ended June 30, 2016 [Japan GAAP] (Consolidated)
2016.5.13: Summary of Business Results for the Fiscal Year Ended March 31, 2016 [Japan GAAP] (Consolidated)
2016.2.10: Summary of Business Results for the Third Quarter Ended December 31, 2015 [Japan GAAP] (Consolidated)